Review structure- and dynamics-based computational design of anticancer drugs

Area of Science:

• Oncology
• Computational Chemistry
• Drug Design

Background:

• Cancer is a complex disease driven by genetic alterations, often leading to treatment resistance and metastasis.
• Existing treatments like drug-cocktails face challenges, necessitating innovative therapeutic strategies.
• Secondary malignancies post-chemotherapy highlight the urgent need for more effective cancer treatments.

Purpose of the Study:

• To review recent advancements in computational drug design methodologies.
• To summarize drug design efforts targeting multiple biomolecules for cancer treatment and prevention.
• To explore the potential of multi-target ligands in overcoming cancer drug resistance.

Main Methods:

• Review of computational drug design techniques.
• Analysis of drug design strategies for multi-target ligands.
• Summary of recent drug design efforts on key cancer targets.

Main Results:

• Computational drug design offers new avenues for developing drugs with enhanced efficacy and selectivity.
• Multi-target ligands represent a promising approach to combat cancer drug resistance.
• Recent efforts focus on targets like topoisomerases, Ras proteins, protein kinases, and histone deacetylases.

Conclusions:

• Computational drug design is pivotal in creating next-generation anti-cancer therapies.
• Multi-target ligand design holds significant potential for improving cancer treatment outcomes.
• Targeting multiple biomolecules offers a rational approach to combat complex cancers.